Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation. Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group. 2015-05-11 China Securities Journal On May 8, 2015,Read More →
Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation. Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group. 2015-05-11 China Securities Journal On May 8, 2015,Read More →
Medisun Medical Group 2015-01-26, Taking the first year of China’s medical reform in 2015 as an opportunity, Mayo and Medisun have joined forces to enter the Chinese medical market in large numbers. It can be said that it is at the right time. Dr. Cao Shengyu, President of Medici MedicalRead More →
Medisun Medical Group 2015-01-26, Taking the first year of China’s medical reform in 2015 as an opportunity, Mayo and Medisun have joined forces to enter the Chinese medical market in large numbers. It can be said that it is at the right time. Dr. Cao Shengyu, President of Medici MedicalRead More →
The International Forum on Heart Failure and Stem Cell Therapies Focus on C-Cure Technology and Launch Ceremony of Phase III Multisite Clinical Trial in China was held jointly by six organizations including Experts Committee of China Council for Medicine International Promotion, National Stem Cell and Regenerative Medicine Industrial Technology InnovationRead More →
Cardio3 BioSciences teams up with Medisun International to create Cardio3 BioSciences Asia Holdings Ltd, a Joint Venture aimed at conducting pivotal clinical programs in Greater China • The minimum of 20M€ funding of the Joint Venture over the next three years is secured by local financial investors led by HongRead More →
Designed using Magazine Hoot. Powered by WordPress.